Literature DB >> 30593619

Full-Length Open Reading Frame Amplification of Hepatitis C Virus.

Ulrik Fahnøe1,2, Jens Bukh3,4.   

Abstract

The purpose of this method is to amplify the full coding sequence of hepatitis C virus (HCV) by a single round reverse transcriptase-polymerase chain reaction (RT-PCR) approach. Our method relies on a highly robust and sensitive RNA extraction procedure and cutting-edge RT-PCR enzymes, all of which have been rigorously tested and optimized. This will not only allow for robust amplification of the entire open reading frame (ORF) of HCV for sequencing by Sanger or next-generation sequencing (NGS), but can also be used for cloning of the ORF of uncharacterized samples and for linkage analysis of mutations on individual genomes spanning the entire ORF. The method has been validated on a variety of samples, including sera from HCV patients and cell-culture supernatants.

Entities:  

Keywords:  Cloning; Full-length ORF RT-PCR; HCV; Hepatitis C virus; Long PCR; Next-generation sequencing; RNA extraction; Sanger sequencing

Mesh:

Substances:

Year:  2019        PMID: 30593619     DOI: 10.1007/978-1-4939-8976-8_5

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  8 in total

1.  High recombination rate of hepatitis C virus revealed by a green fluorescent protein reconstitution cell system.

Authors:  Andrea Galli; Ulrik Fahnøe; Jens Bukh
Journal:  Virus Evol       Date:  2021-12-23

2.  Mutations Identified in the Hepatitis C Virus (HCV) Polymerase of Patients with Chronic HCV Treated with Ribavirin Cause Resistance and Affect Viral Replication Fidelity.

Authors:  Niels Mejer; Ulrik Fahnøe; Andrea Galli; Santseharay Ramirez; Ola Weiland; Thomas Benfield; Jens Bukh
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

3.  Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c.

Authors:  Santseharay Ramirez; Carlota Fernandez-Antunez; Lotte S Mikkelsen; Jannie Pedersen; Yi-Ping Li; Jens Bukh
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

4.  Versatile SARS-CoV-2 Reverse-Genetics Systems for the Study of Antiviral Resistance and Replication.

Authors:  Ulrik Fahnøe; Long V Pham; Carlota Fernandez-Antunez; Rui Costa; Lizandro René Rivera-Rangel; Andrea Galli; Shan Feng; Lotte S Mikkelsen; Judith M Gottwein; Troels K H Scheel; Santseharay Ramirez; Jens Bukh
Journal:  Viruses       Date:  2022-01-18       Impact factor: 5.048

5.  Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure.

Authors:  David A Smith; Carlota Fernandez-Antunez; Andrea Magri; Rory Bowden; Nimisha Chaturvedi; Jacques Fellay; John McLauchlan; Graham R Foster; William L Irving; Peter Simmonds; Vincent Pedergnana; Santseharay Ramirez; Jens Bukh; Eleanor Barnes; M Azim Ansari
Journal:  Nat Commun       Date:  2021-10-20       Impact factor: 17.694

6.  High-Titer Hepatitis C Virus Production in a Scalable Single-Use High Cell Density Bioreactor.

Authors:  Anna Offersgaard; Carlos Rene Duarte Hernandez; Anne Finne Pihl; Nandini Prabhakar Venkatesan; Henrik Krarup; Xiangliang Lin; Udo Reichl; Jens Bukh; Yvonne Genzel; Judith Margarete Gottwein
Journal:  Vaccines (Basel)       Date:  2022-02-07

7.  Development of a downstream process for the production of an inactivated whole hepatitis C virus vaccine.

Authors:  Keven Lothert; Anna F Offersgaard; Anne F Pihl; Christian K Mathiesen; Tanja B Jensen; Garazi Peña Alzua; Ulrik Fahnøe; Jens Bukh; Judith M Gottwein; Michael W Wolff
Journal:  Sci Rep       Date:  2020-10-01       Impact factor: 4.379

8.  HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4.

Authors:  Long V Pham; Martin Schou Pedersen; Ulrik Fahnøe; Carlota Fernandez-Antunez; Daryl Humes; Kristian Schønning; Santseharay Ramirez; Jens Bukh
Journal:  Gut       Date:  2021-04-08       Impact factor: 23.059

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.